The Mice Model Market size is forecast to experience steady expansion, projected to reach US$ 3.29 billion by 2034, rising from US$ 2.00 billion in 2025. The market is anticipated to register a Compound Annual Growth Rate (CAGR) of 5.75% during the forecast period of 2026–2034.
Mice Model Market AnalysisThe global mice model market forecast indicates stable and predictable growth, primarily driven by the consistent and escalating demand for high-quality preclinical research models across the pharmaceutical and biotechnology sectors. This growth is significantly bolstered by groundbreaking advancements in genetic engineering technologies, most notably CRISPR/Cas9, which enable the rapid and precise creation of complex, humanized models. As the global incidence and complexity of chronic diseases, particularly cancer, continue to rise, there is an ever-increasing requirement for in vivo systems to facilitate drug discovery, conduct rigorous toxicology studies, and accelerate the development of personalized medicine approaches. The market is witnessing greater collaboration between academic research institutions and commercial model providers to industrialize the supply chain of specialized models.
Mice Model Market OverviewMice models are indispensable assets in modern biomedical research, serving as critical platforms for elucidating disease pathology, assessing the efficacy of novel therapeutic compounds, and conducting comprehensive safety and toxicity evaluations. The market encompasses a wide array of models, including standard inbred and outbred strains, highly specialized genetically engineered (transgenic, knockout, knock-in) models, and increasingly complex humanized mice. Market dynamics are characterized by intensive Research and Development (R&D) investments, particularly in developing models that better mimic human conditions. Key technological adoption trends include the widespread use of gene-editing techniques like CRISPR, as well as the integration of stem cell-based approaches to improve model relevance.
Strategic Insights
Mice Model Market Drivers and OpportunitiesMarket Drivers:
- Rising Demand for Preclinical Studies in Drug Development: Mandatory regulatory requirements and the need for robust efficacy and safety data necessitate the use of in vivo animal models, driving the fundamental demand for laboratory mice in the drug pipeline.
- Advancements in Genetic Engineering Technologies Including CRISPR: The revolutionary precision and speed of gene-editing tools such as CRISPR/Cas9 have dramatically lowered the barrier to creating highly specific mouse models, significantly accelerating disease modeling and target validation.
- Growing Prevalence of Cancer and Other Chronic Diseases: The increasing global prevalence of complex illnesses, especially oncology and neurodegenerative disorders, necessitates more relevant and sophisticated animal models to understand disease mechanisms and test targeted therapies effectively.
Market Opportunities:
- Development of Humanized Mice Models for Personalized Medicine: The creation of humanized mice, often engineered to possess human immune systems or specific human gene sequences, represents a major opportunity, allowing for more clinically predictive preclinical testing tailored for specific patient populations.
- Expansion in Emerging Markets with Increasing Research Infrastructure: Countries in the Asia-Pacific and Latin America regions are rapidly investing in biomedical research infrastructure and clinical trial capabilities, opening new avenues for commercial model providers to expand their service and supply networks.
- Strategic Partnerships Between Contract Research Organizations (CROs) and Pharmaceutical Companies: Closer integration between CROs that utilize mice models and pharmaceutical companies that develop drugs allows for customized model creation and integrated preclinical testing services, optimizing research timelines and resource utilization.
The Mice Model Market share is analyzed across various segments to illustrate the range of models, supporting services, utilized technologies, and primary indications driving demand. Below is the standard segmentation approach used in most industry reports:
By Type:
- Inbred Mice
- Outbred Mice
- Genetically Engineered Mice
- Hybrid Mice
- Surgically Modified Mice
- Spontaneous Mutant Mice
By Service:
- Breeding
- Cryopreservation
- Model-in Licensing
- Genetic Testing
- Quarantine
By Technology:
- CRISPR
- Microinjection
- Embryonic Stem Cell Injection
- Nuclear Transfer
By Indication:
- Oncology Studies
- Immunology & Inflammation Studies
- Endocrine Metabolic Studies
- Cardiovascular Studies
- Central Nervous System
By Geography:
- North America
- Europe
- Asia Pacific
- South & Central America
- Middle East & Africa
Market Report Scope
Mice Model Market Share Analysis by GeographyNorth America holds the largest market share, with the Asia-Pacific region exhibiting the highest CAGR during the forecast period.
The market growth trajectory varies by region, influenced by factors such as government research funding, pharmaceutical industry presence, and regulatory oversight of animal research. Below is a summary of market share and trends by region:
North America
- Market Share: Dominates the global market due to the massive presence of major pharmaceutical and biotech companies, substantial government and private funding for biomedical research, and a highly established network of commercial model providers.
- Key Drivers: Leading adoption rate of advanced genetically engineered and humanized models.
- Trends: Increasing outsourcing of model development and maintenance services to specialized vendors, and a focus on models for complex, personalized cancer therapy research.
Europe
- Market Share: Holds a significant share, supported by strong government-funded research programs (e.g., Horizon Europe), strict regulatory frameworks ensuring quality, and major academic research clusters.
- Key Drivers: Collaborative projects across multiple European nations requiring standardized model supply.
- Trends: Emphasis on developing and sharing standardized, high-quality models across research networks to enhance reproducibility, often focused on infectious diseases and rare genetic disorders.
Asia-Pacific
- Market Share: Fastest-growing region globally, fueled by rapid investments in the biomedical research sector, expanding domestic pharmaceutical industries, and increasing clinical research activities, particularly in China and India.
- Key Drivers: Establishment of new, state-of-the-art research centers and biotech hubs.
- Trends: Fast growth in demand for both standardized models for toxicology screening and complex GEM models to support a burgeoning drug discovery pipeline.
South and Central America
- Market Share: Emerging market with developing research capabilities and expanding clinical research activities, especially in vaccine and infectious disease research.
- Key Drivers: Growing need for specialized models for region-specific diseases.
- Trends: Focus on establishing local breeding and maintenance facilities to ensure a stable supply of high-quality, regionally relevant models.
Middle East and Africa
- Market Share: Developing market with growth potential driven by government investments in creating world-class healthcare and research facilities as part of broader economic diversification efforts.
- Key Drivers: Demand for models to study region-specific infectious diseases and genetic disorders.
- Trends: Partnerships with global suppliers to import high-quality models and transfer technology for local breeding and genetic manipulation.
The competitive landscape is defined by a few global giants who dominate model supply and distribution, alongside highly specialized, technology-focused companies focusing on cutting-edge genetic engineering. Major vendors prioritize model quality, genetic integrity, and scientific support services.
This competitive environment pushes vendors to differentiate through:
- Genetic Precision and Quality: Ensuring the highest genetic purity and health standards for every model supplied, backed by rigorous quality control and genetic testing services.
- Speed of Model Generation: Utilizing advanced technologies like CRISPR to dramatically reduce the time required to develop a custom genetically engineered mouse model.
- Scientific Service Integration: Offering end-to-end services, from model design and breeding to in vivo pharmacology and phenotyping studies, providing complete research solutions.
- Charles River Laboratories
- The Jackson Laboratory
- Taconic Biosciences
- GenOway S.A.
- Envigo (Inotiv, Inc.)
- TRANS GENIC INC.
- Janvier Labs
- Ozgene Pty Ltd.
- Crown Bioscience Inc.
Disclaimer: The companies listed above are not ranked in any particular order.
Mice Model Market News and Recent Developments- Charles River Laboratories announced enhancements to its International Genetic Standardization (IGS) program, offering a wide range of immunodeficient, transgenic, and humanized mouse models. The company introduced advanced humanized NCG and PBMC models and the rasH2 transgenic mouse for accelerated carcinogenicity testing, supporting oncology and toxicology research.
- The Jackson Laboratory unveiled the CAST/EiJ strain, naturally susceptible to severe COVID-19 variants, enabling vaccine and therapeutic testing without genetic modification. Additionally, JAX introduced mouse models for alternating hemiplegia of childhood (AHC) and advanced work on genetically engineered models for late-onset Alzheimer’s disease (LOAD) using CRISPR and transgenes based on human risk factors.
- Envigo expanded its portfolio with B-NDG hIL15 mice expressing human IL-15 for NK-cell development and B-NDG B2m models optimized for IgG pharmacokinetics. The company also completed the acquisition of Horizon Discovery’s research models unit, integrating CRISPR-edited mice into its offerings for advanced genetic research.
The "Mice Model Market Size and Forecast (2021–2034)" report provides a detailed analysis of the market covering below areas:
- Mice Model Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope.
- Mice Model Market trends, as well as market dynamics such as drivers, restraints, and key opportunities.
- Detailed PEST and SWOT analysis.
- Mice Model Market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments.
- Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments in the Mice Model Market.
- Detailed company profiles.
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Type, Service, Technology, Indication, End User, Application, and Mode
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Saudi Arabia, South Africa, South Korea, Spain, United Arab Emirates, United Kingdom, United States
Frequently Asked Questions
North America leads the market. This dominance is attributed to the presence of the world's largest pharmaceutical companies, high government and private R&D spending, and the concentration of major model providers.
Oncology Studies constitute the largest indication segment. This is due to the complexity of cancer research, the high number of drug candidates in the oncology pipeline, and the need for various xenograft and immunocompetent models.
The market's fundamental growth is driven by preclinical research demand, genetic technology advancement, and disease burden
Genetically Engineered Mice (GEMs) models, including knockouts and transgenics, hold the largest share and are the fastest-growing segment due to their specificity and necessity in modern target validation and disease modeling.
The global market is valued at approximately US$ 2.00 billion. It is projected to reach US$ 3.29 billion by 2034, reflecting a compound annual growth rate (CAGR) of 5.75% during the forecast period from 2026 to 2034.
Yes! We provide a free sample of the report, which includes Report Scope (Table of Contents), report structure, and selected insights to help you assess the value of the full report. Please click on the "Download Sample" button or contact us to receive your copy.
Absolutely - analyst assistance is part of the package. You can connect with our analyst post-purchase to clarify report insights, methodology or discuss how the findings apply to your business needs.
Once your order is successfully placed, you will receive a confirmation email along with your invoice.
• For published reports: You'll receive access to the report within 4-6 working hours via a secured email sent to your email.
• For upcoming reports: Your order will be recorded as a pre-booking. Our team will share the estimated release date and keep you informed of any updates. As soon as the report is published, it will be delivered to your registered email.
We offer customization options to align the report with your specific objectives. Whether you need deeper insights into a particular region, industry segment, competitor analysis, or data cut, our research team can tailor the report accordingly. Please share your requirements with us, and we'll be happy to provide a customized proposal or scope.
The report is available in either PDF format or as an Excel dataset, depending on the license you choose.
The PDF version provides the full analysis and visuals in a ready-to-read format. The Excel dataset includes all underlying data tables for easy manipulation and further analysis.
Please review the license options at checkout or contact us to confirm which formats are included with your purchase.
Our payment process is fully secure and PCI-DSS compliant.
We use trusted and encrypted payment gateways to ensure that all transactions are protected with industry-standard SSL encryption. Your payment details are never stored on our servers and are handled securely by certified third-party processors.
You can make your purchase with confidence, knowing your personal and financial information is safe with us.
Yes, we do offer special pricing for bulk purchases.
If you're interested in purchasing multiple reports, we're happy to provide a customized bundle offer or volume-based discount tailored to your needs. Please contact our sales team with the list of reports you're considering, and we'll share a personalized quote.
Yes, absolutely.
Our team is available to help you make an informed decision. Whether you have questions about the report's scope, methodology, customization options, or which license suits you best, we're here to assist. Please reach out to us at sales@theinsightpartners.com, and one of our representatives will get in touch promptly.
Yes, a billing invoice will be automatically generated and sent to your registered email upon successful completion of your purchase.
If you need the invoice in a specific format or require additional details (such as company name, GST, or VAT information), feel free to contact us, and we'll be happy to assist.
Yes, certainly.
If you encounter any difficulties accessing or receiving your report, our support team is ready to assist you. Simply reach out to us via email or live chat with your order information, and we'll ensure the issue is resolved quickly so you can access your report without interruption.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Get Free Sample For